A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.

Trial Profile

A phase I/ II, open label study to assess the efficacy and safety of ABTL0812 in combination with paclitaxel and carboplatin in patients with advanced endometrial cancer or squamous NSCLC.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs ABTL 0812 (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Ability Pharmaceuticals
  • Most Recent Events

    • 22 Nov 2016 According to an Ability Pharmaceuticals media release, this study is initially being conducted in Barcelona at Vall d'Hebron Institute of Oncology (VHIO) and Institut Catala d'Oncologia (ICO) by Dr. Ana Oaknin and Dr. Ernest Nadal as principal investigators for endometrial cancer and lung cancer respectively. Dr. Jordi Rodon (VHIO) is the coordinating investigator. Additional sites in France and Spain will be added over the next 6 months.
    • 29 Jul 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top